Figure 2.

CSF delivery of scAAV9.CB.CLN6 prevents increased astrocyte reactivity in the DLG, V1, and SC

(A–C) A single, postnatal day 1 injection of scAAV9.CB.CLN6 delivered via CSF prevents GFAP⁺ astrocyte reactivity (green) in the (A) DLG, (B) V1, and (C) SC until 9 months of age. n = 6/treatment for each time point, represented by equal numbers of males and females. Mean ± SEM, one-way ANOVA for each time point, Bonferroni correction. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.